Technical Analysis for CVM - Cel-Sci Corporation

Grade Last Price % Change Price Change
F 2.05 1.99% 0.04
CVM closed up 1.99 percent on Monday, March 18, 2024, on 65 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Flat Down Down

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
NR7 Range Contraction 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 200 DMA Bearish 1.99%
MACD Bearish Signal Line Cross Bearish 1.99%
Stochastic Reached Oversold Weakness 1.99%
Inside Day Range Contraction 1.99%
Oversold Stochastic Weakness 1.99%
20 DMA Resistance Bearish -2.84%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 11 hours ago
Reversed from Up about 12 hours ago
Gap Up Closed about 15 hours ago
Gap Up Partially Closed about 15 hours ago
Gapped Up (Partial) about 16 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cel-Sci Corporation Description

CEL-SCI Corporation engages in the research and development of drugs and vaccines. The company's principal product, Multikine, is under Phase III clinical trial for the treatment of head and neck cancer. The Multikine is an immunotherapeutic agent consisting of a mixture of cytokines that produce an anti-tumor immune response. It also develops Ligand Epitope Antigen Presentation System (LEAPs), a heteroconjugate technology that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer. The company, through its LEAPS technology, develops a peptide treatment for H1N1 hospitalized patients; and CEL-2000, a rheumatoid arthritis vaccine. CEL-SCI Corporation was founded in 1983 and is based in Vienna, Virginia.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Immunology Immune System Immunotherapy Vaccines Autoimmunity Rheumatoid Arthritis Vaccination Transplantation Cytokine Head And Neck Cancer Antigen Immune Response Allergies

Is CVM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.23
52 Week Low 1.04
Average Volume 317,532
200-Day Moving Average 2.05
50-Day Moving Average 2.42
20-Day Moving Average 2.16
10-Day Moving Average 2.18
Average True Range 0.15
RSI (14) 40.12
ADX 16.28
+DI 16.29
-DI 23.06
Chandelier Exit (Long, 3 ATRs) 2.04
Chandelier Exit (Short, 3 ATRs) 2.42
Upper Bollinger Bands 2.38
Lower Bollinger Band 1.94
Percent B (%b) 0.25
BandWidth 20.41
MACD Line -0.10
MACD Signal Line -0.09
MACD Histogram -0.0043
Fundamentals Value
Market Cap 102.46 Million
Num Shares 50 Million
EPS -0.73
Price-to-Earnings (P/E) Ratio -2.81
Price-to-Sales 11797.42
Price-to-Book 9.30
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.19
Resistance 3 (R3) 2.18 2.14 2.16
Resistance 2 (R2) 2.14 2.10 2.14 2.15
Resistance 1 (R1) 2.09 2.08 2.07 2.10 2.15
Pivot Point 2.05 2.05 2.04 2.05 2.05
Support 1 (S1) 2.00 2.01 1.98 2.01 1.95
Support 2 (S2) 1.96 1.99 1.96 1.95
Support 3 (S3) 1.91 1.96 1.94
Support 4 (S4) 1.92